A new meta-analysis published in the Journal of the National Comprehensive Cancer Network has provided updated evidence that methylphenidate-type psychostimulants can provide meaningful relief for cancer-related fatigue. According to the findings, the use of prescription medications such as methylphenidate (MPH) or dexmethylphenidate (d-MPH) was associated with significant improvements in fatigue scores across widely validated scales relative to placebo.
What makes this finding particularly noteworthy is the time dimension: the benefit isn't fully apparent in the first couple of weeks, but by around five weeks it reaches a level that genuinely matters in terms of patients' daily energy and function. "For people dealing with a symptom that can be profoundly disabling, that is a meaningful contribution," noted lead author Bruno Almeida Costa, MD, of The University of Texas MD Anderson Cancer Center.
"However, those take time—often eight to 12 weeks of consistent engagement—to reach their full benefit. Methylphenidate could serve as a bridge during that window, providing earlier relief while the longer-term strategies take effect," Dr. Costa added.
The analysis was based on nine different double-blind, individually randomized, parallel-group, placebo-controlled phase II/III trials evaluating either MPH or d-MPH in adults with advanced cancer or actively receiving cancer-directed treatment. There were 823 total patients included, and the studies were published between May 2006 and July 2024.
The findings highlight that methylphenidate has one of the "longest-standing and best-documented safety records among actively prescribed controlled substances," with a history dating back to 1955. It is approved for use in patients as young as 6 years old for ADHD and narcolepsy, and there was no statistically significant increase in side effects compared with placebo.
Dr. Costa emphasized that while methylphenidate can provide immediate relief, it should not be seen as a standalone solution to cancer-related fatigue. "We are seeing a worrying trend of cancer diagnoses in younger adults who are building careers, raising families, and leading very active lives," he noted. "For this population, fatigue can be especially disruptive because there's so much they need and want to do."
Chandana Banerjee, MD, MPA, HMDC, FAAHPM, Vice-Chair of the NCCN Clinical Practice Guidelines in Oncology Panel for Cancer-Related Fatigue, who was not involved with this research, commented that the emerging evidence underscores a broader principle: "That precision, thoughtful patient selection and careful monitoring can transform modest effects into meaningful clinical impact and an improved patient experience."
The NCCN Guidelines for Cancer-Related Fatigue include the option to consider the use of methylphenidate in certain circumstances, while noting the need for caution around dosing, schedule, and investigation into underlying causes.
While cognitive-behavioral therapy, exercise, and mind-body practices remain the strongest evidence-based strategies for managing cancer-related fatigue, methylphenidate can serve as a practical tool to help preserve daily functioning and support engagement with other treatments.
